WARNER-LAMBERT's CAPILL BEING EVALUATED BY 15 DRUG COMPANIES
Executive Summary
WARNER-LAMBERT's CAPILL BEING EVALUATED BY 15 DRUG COMPANIES, the firm reported at a meeting with securities analysts in New York City on Oct. 18. The Capill digestible capsule product is one of the first potential commercial applications of Warner-Lambert's Novon starch plastic technology. Warner-Lambert has started to produce small quantities of the material "for customer evaluation and testing" at its new R&D facilities in Arlesheim, Switzerland. The company says it will be adding a pilot plant to that facility, capable of producing several million pounds of material per year, to expedite customer evaluations. The additional pilot plant is expected to be completed early in 1991. Novon's first commercial production plant will be in Rockford, Illinois and is scheduled for completion by the end of 1991. It is intended to produce more than 100 mil. pounds of Novon per year. Warner-Lambert now expects to begin producing commercial quantities "by early 1992," Chairman Joseph Williams said. Warner-Lambert told analysts that it is "confident we have a viable product." Primary technical innovations have been the expansion of Novon's flexural performance by blending the starch with different polymers, and new formulations of Novon that provide a wide range of water and humidity resistance. Warner-Lambert now holds more than 30 patents relating to Novon. The company has targeted four major markets for Novon: food packaging; non-food packaging; personal and health care; and disposable or short life-cycle products. Warner-Lambert also stressed a desire to "create new applications for Novon not associated with traditional plastics processing," including "non-wovens, fiber spinning, coatings and paper applications."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth